Active Suppression Induced by Repetitive Self-Epitopes Protects against EAE Development

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Puentes, Fabiola ^a   Dickhaut, Katharina ^a   Hofstätter, Maria ^a   Falk, Kirsten ^a   Rötzschke, Olaf ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FREUND ADJUVANT; IMMUNOSUPPRESSIVE AGENT; MYELIN PROTEOLIPID PROTEIN[139-151]; OLIGOMER; SERYLVALYLSERYLSERYLPHENYLALANYLGLUTAMYLARGINYLPHENYLALANYLGLUTAMYLISOLEUCYLPHENYLALALNYLPROLYLLYSINE; SYNTHETIC PEPTIDE; T LYMPHOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE CONTROL; EX VIVO STUDY; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGOMERIZATION; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ANIMALS; AUTOANTIGENS; CELL PROLIFERATION; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOSUPPRESSION; MICE; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; T-LYMPHOCYTES;

ANIMALIA; MUS;

EID: 84878514705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064888     Document Type: Article

References (57)

1. Watanabe K, Sukumaran V, Veeraveedu PT, Thandavarayan RA, Gurusamy N, et al. (2011) Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis. Inflamm Allergy Drug Targets 10: 218-225.
2. van Herwijnen MJ, Wieten L, van der Zee R, van Kooten PJ, Wagenaar-Hilbers JP, et al. (2012) Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc Natl Acad Sci U S A 109: 14134-14139.
3. Liblau RS, Tisch R, Shokat K, Yang X, Dumont N, et al. (1996) Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc Natl Acad Sci U S A 93: 3031-3036.
4. Hogan SP, Foster PS, Charlton B, Slattery RM, (1998) Prevention of Th2-mediated murine allergic airways disease by soluble antigen administration in the neonate. Proc Natl Acad Sci U S A 95: 2441-2445.
5. Liu Z, Harris PE, Colovai AI, Reed EF, Maffei A, et al. (1995) Suppression of the indirect pathway of T cell reactivity by high doses of allopeptide. Autoimmunity 21: 173-184.
6. Chung Y, Chang SY, Kang CY, (1999) Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. J Immunol 163: 3692-3698.
7. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, et al. (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180: 1961-1966.
8. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, et al. (2004) Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 101: 4228-4233.
9. Falk K, Rotzschke O, Santambrogio L, Dorf ME, Brosnan C, et al. (2000) Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides. J Exp Med 191: 717-730.
10. Stienekemeier M, Falk K, Rotzschke O, Weishaupt A, Schneider C, et al. (2001) Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proc Natl Acad Sci U S A 98: 13872-13877.
11. Piaggio E, Mars LT, Cassan C, Cabarrocas J, Hofstatter M, et al. (2007) Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance. Proc Natl Acad Sci U S A 104: 9393-9398.
12. Johnson KP, (2012) Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 12: 371-384.
13. Teitelbaum D, Aharoni R, Arnon R, Sela M, (1988) Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci U S A 85: 9724-9728.
14. Farina C, Then Bergh F, Albrecht H, Meinl E, Yassouridis A, et al. (2001) Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 124: 705-719.
15. Aharoni R, Meshorer A, Sela M, Arnon R, (2002) Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol 126: 58-68.
16. Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, et al. (2011) Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 6: e22444.
17. Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, et al. (2012) Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 259: 898-905.
18. Rotzschke O, Falk K, Strominger JL, (1997) Superactivation of an immune response triggered by oligomerized T cell epitopes. Proc Natl Acad Sci U S A 94: 14642-14647.
19. Mack J, Falk K, Rotzschke O, Walk T, Strominger JL, et al. (2001) Synthesis of linear and comb-like peptide constructs containing up to four copies of a T cell epitope and their capacity to stimulate T cells. J Pept Sci 7: 338-345.
20. Falk K, Rotzschke O, Strominger JL, (2000) Antigen-specific elimination of T cells induced by oligomerized hemagglutinin (HA) 306-318. Eur J Immunol 30: 3012-3020.
21. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, et al. (1992) Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127: 5-24.
22. O'Farrell AM, Liu Y, Moore KW, Mui AL, (1998) IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and-independent pathways. EMBO J 17: 1006-1018.
23. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L, (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536-1541.
24. Ohara J, Paul WE, (1985) Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 315: 333-336.
25. Lowenthal JW, Corthesy P, Tougne C, Lees R, MacDonald HR, et al. (1985) High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J Immunol 135: 3988-3994.
26. Santambrogio L, Hochwald GM, Saxena B, Leu CH, Martz JE, et al. (1993) Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J Immunol 151: 1116-1127.
27. Gross JA, Callas E, Allison JP, (1992) Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 149: 380-388.
28. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, et al. (2005) Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 11: 1118-1124.
29. Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD, (2012) Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335: 723-727.
30. McGeachy MJ, Stephens LA, Anderton SM, (2005) Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175: 3025-3032.
31. Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, et al. (2006) Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25: 941-952.
32. Anderson CF, Oukka M, Kuchroo VJ, Sacks D, (2007) CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
33. DiPaolo RJ, Glass DD, Bijwaard KE, Shevach EM, (2005) CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J Immunol 175: 7135-7142.
34. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM, (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950.
35. Paglinawan R, Malipiero U, Schlapbach R, Frei K, Reith W, et al. (2003) TGFbeta directs gene expression of activated microglia to an anti-inflammatory phenotype strongly focusing on chemokine genes and cell migratory genes. Glia 44: 219-231.
36. Rajagopalan G, Kudva YC, Sen MM, Marietta EV, Murali N, et al. (2006) IL-10-deficiency unmasks unique immune system defects and reveals differential regulation of organ-specific autoimmunity in non-obese diabetic mice. Cytokine 34: 85-95.
37. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA, (2009) Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 9: 447-453.
38. You S, Chen C, Lee WH, Brusko T, Atkinson M, et al. (2004) Presence of diabetes-inhibiting, glutamic acid decarboxylase-specific, IL-10-dependent, regulatory T cells in naive nonobese diabetic mice. J Immunol 173: 6777-6785.
39. Diener E, Feldmann M, (1972) Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev 8: 76-103.
40. Liacopoulos P, Couderc J, Gille MF, (1971) Competition of antigens during induction of low zone tolerance. Eur J Immunol 1: 359-363.
41. Sharma SD, Nag B, Su XM, Green D, Spack E, et al. (1991) Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci U S A 88: 11465-11469.
42. Miller SD, Turley DM, Podojil JR, (2007) Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 7: 665-677.
43. Ruiz PJ, Garren H, Ruiz IU, Hirschberg DL, Nguyen LV, et al. (1999) Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J Immunol 162: 3336-3341.
44. Huan J, Subramanian S, Jones R, Rich C, Link J, et al. (2004) Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol 172: 4556-4566.
45. Zinkernagel RM, Hengartner H, (2001) Regulation of the immune response by antigen. Science 293: 251-253.
46. Snapper CM, Kehry MR, Castle BE, Mond JJ, (1995) Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells. A redefinition of the TI-2 vs T cell-dependent antigen dichotomy. J Immunol 154: 1177-1187.
47. Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, et al. (2012) Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol 188: 4644-4653.
48. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, et al. (2007) Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 204: 57-63.
49. Mauri C, Gray D, Mushtaq N, Londei M, (2003) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197: 489-501.
50. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK, (2000) Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 12: 597-605.
51. Almeras L, Meresse B, Seze J, De Lefranc D, Dubucquoi S, et al. (2002) Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. Eur Cytokine Netw 13: 200-206.
52. Mekala DJ, Alli RS, Geiger TL, (2005) IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Proc Natl Acad Sci U S A 102: 11817-11822.
53. Asadullah K, Sterry W, Volk HD, (2003) Interleukin-10 therapy-review of a new approach. Pharmacol Rev 55: 241-269.
54. Itoh S, ten Dijke P, (2007) Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol 19: 176-184.
55. Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, et al. (2005) Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 4: 450-459.
56. Cottrez F, Groux H, (2001) Regulation of TGF-beta response during T cell activation is modulated by IL-10. J Immunol 167: 773-778.
57. Carrier Y, Yuan J, Kuchroo VK, Weiner HL, (2007) Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J Immunol 178: 172-178.